mardi 15 janvier 2019

Onco Actu du 15 janvier 2019


1. BIOLOGIE



Tumor Hypoxia Associated With Cancer Driver Mutation Signatures in 19 Tumor Types [Genome Web]











4.10 DÉP., DIAG. & PRONO. - POUMON



Lung cancer screening complications may be higher than expected [Reuters]










4.9 DÉP., DIAG. & PRONO. - SEIN



GPs could use breast cancer 'calculator' to predict risk to women [The Guardian]











Researchers develop comprehensive new way to predict breast cancer risk [Cancer Research UK]










5.10 TRAITEMENTS - ESSAIS



ASLAN Pharmaceuticals announces study results from phase 2 study of varlitinib in first-line gastric cancer [Aslan]











Aslan fails to roar as lead drug flunks phase 2 trial [Fierce Biotech]











Aslan turns focus to biliary tract cancer as lead drug flops in PhII gastric cancer study [EndPoints]











5.12 IMMUNOTHÉRAPIES



Researchers Uncover Major Clue In Predicting Response To Immunotherapy [Forbes]











Parker-backed cancer scientists shine a light on an emerging pathway in pancreatic cancer [EndPoints]











Highly mutated cancers respond better to immune therapy [Nature]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



Merck's Keytruda slashes death risk by 31% in esophageal cancer victory [Fierce Pharma]










Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10) [Merck]











5.12.6 IMMUNOTHÉRAPIES - AMM



European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma [BMS]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Top product forecasts for 2019 [Nature Reviews Drug Discovery]











5.2 PHARMA



Sean Bohen to leave AstraZeneca as exodus continues [Fierce Biotech]











5.3 TRAITEMENTS - FDA, EMA, NICE...



If the shutdown drags on at FDA, it will put anticipated new treatments in jeopardy [STAT]











EMA to lose 25% of staff as hard Brexit approaches [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma [Exelixis]











5.4 TRAITEMENTS - ECONOMIE



Think Generics Will Lower the Cost of Chemo? Think Again [Forbes]










6.1 OBSERVATION



You’re Not Getting Much Taller, America. But You Are Getting Bigger. [NY Times]











6.10.1 POLITIQUES (USA)



House Democrats launch drug pricing investigation into 12 major companies [STAT]











6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES



How online crowdfunding supports cancer quacks (part 2) [Respectful Insolence]











6.6 PUBLICATIONS



Plan S: What About Researchers? [The Scholarly Kitchen]











6.7.3 DMP



Early research on Apple's Health Records service suggests patients generally like it [CNBC]